How do you manage moist desquamation when treating breast cancer?

In my experience treating patients with breast cancer, those undergoing postmastectomy radiation and patients with surgically unresectable gross chest wall disease who require use of bolus, are most likely to develop moist desquamation. I agree that for patients undergoing adjuvant postmastectomy radiation, while skin erythema is expected and even desirable at the completion of treatment, treatment should be tailored to avoid confluent moist desquamation whenever possible. The frequency of bolus placement should be adjusted or discontinued altogether in patients who demonstrate early brisk skin erythema (not related to infection), for example, during the third week of a 5 week course of chest wall radiation.

I have found Mepilex Ag (silver...